TA127 Multiple sclerosis - natalizumab: review decision - July 2013 information
History
A list of downloadable documents created during development.
Background information
-
-
-
TA127 Multiple sclerosis - natalizumab: review poposal - May 2013 information
-
Multiple sclerosis - natalizumab: Appendix A - provisional matrix of stakeholders (PDF 39 KB)
-
-
-
Appendix A: decision paper considered by the Institute's Guidance Executive (PDF 45 KB)
-
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 138 KB)
-
NICE recommends natalizumab for the treatment of multiple sclerosis information
-
NICE recommends natalizumab for the treatment of multiple sclerosis (PDF 34 KB)
-
TA127 Multiple sclerosis - natalizumab: distribution list (PDF 19 KB)
Multiple sclerosis - natalizumab: Appraisal consultation document
Multiple sclerosis - natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis: Final appraisal determination
-
Multiple sclerosis - natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis: Final appraisal determination
-
Consultee and commentator comments on the ACD
-
-
-
-
-
-
-
-
-
Department of Health Social Services and Public Safety for Northern Ireland (PDF 19 KB)
-
-
-
Expert comments on the ACD
-
Caroline Haynes, patient expert, nominated by Multiple Sclerosis Trust (PDF 20 KB)
-
Mark Priest, patient expert, nominated by Multiple Sclerosis Trust (PDF 34 KB)
-
-
Multiple sclerosis - natalizumab: Evaluation report
-
Multiple sclerosis - natalizumab: Evaluation report
-
Multiple sclerosis - natalizumab: Evaluation report - Pre-meeting briefing (PDF 96 KB)
-
-
Multiple sclerosis - natalizumab: Evaluation report - Evidence Review Group Report (PDF 517 KB)
-
-
Multiple sclerosis - natalizumab: Evaluation report Manufacturer Questionnaire (PDF 437 KB)
-
Multiple sclerosis - natalizumab: Evaluation report - NICE Clarification letter (PDF 36 KB)
-
Multiple sclerosis - natalizumab: Manufacturer submissions
-
-
-
Multiple sclerosis - natalizumab: Non-Manufacturer submissions
-
-
-
-
-
-